Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about $6.9 billion in the seven major pharmaceutical markets in 2008.
Scope
- In-depth analysis of the current and future antihormonal therapies market across the US, 5EU and Japan, plus a rest of world snapshot
- Antihormonal therapy sales forecasts for brands and generics from 2008 to 2018
- Assessment of the leading cancer brands and drug classes to identify key success factors within this sector
- Evaluation of the strategies of leading players in the antihormonals market
Highlights
The antihormonals market was worth $6.9 billion in 2008 across the seven major pharmaceutical markets. Its growth within the next decade, at a marginal CAGR of 0.1%, will be predominantly limited by patent expiries of leading brands.
In 2008, Arimidex
(anastrozole; AstraZeneca
), Lupron
(leuprolide; Takeda/Abbott
) and Casodex
(bicalutamide; AstraZeneca
) were the three leading antihormonal brands in terms of sales. These will remain the top three brands through to 2018, even though Arimidex and Casodex will lose around 40% of their brand value due to generic competition.
In a mature market, the importance of product lifecycle management is high. AstraZeneca was the key player in the market in 2008, with an antihormonals portfolio valued at over $3.4 billion. With successful lifecycle management and a considerable investment in marketing activities, AstraZeneca has built a strong brand presence for its products.
Reasons to Purchase
- Quantify the performance of each of the marketed antihormonal therapy cancer brands in the seven major markets over the period 2008 to 2018
- Acquire a detailed account of antihormonal therapy cancer brand dynamics and the events that drive and limit their market growth
- Benchmark the antihormonal therapy cancer brands against generics and rest of class and align their 7MM performance with a rest of world snapshot
Table of Contents108 pagesPublication Date : July 2009
)
